依奇珠单抗和司库奇尤单抗治疗中重度斑块型银屑病的临床价值分析

Clinical value analysis of ecizumab and secuchiumab in the treatment of m oderate to severe plaque psoriasis

目的:探讨依奇珠单抗与司库奇尤单抗在中重度斑块型银屑病治疗中的临床应用效果。方法:选取2021年7月至2022年9月汕头市皮肤性病防治院收治的79例中重度斑块型银屑病患者作为研究对象。采用抛硬币分组的方法将患者分为试验组(n=42)和对照组(n=37)。试验组采用依奇珠单抗治疗,对照组采用司库奇尤单抗治疗,对两组患者的治疗结果进行对比和分析。结果:两组患者治疗前及治疗后4周、8周、12周的银屑病皮损面积及严重指数(PASI)评分比较差异无统计学意义(P>0.05)。两组患者的不良反应发生率对比差异无统计学意义(P>0.05)。试验组患者的治疗满意率为95.24%,高于对照组的94.59%,但组间差异无统计学意义(P>0.05)。结论:依奇珠单抗与司库奇尤单抗在中重度斑块型银屑病的治疗中均具有良好的效果,同时安全性均较好。

Objective:To investigate the clinical efficacy of ecizumab and secuchiumab in the treatment of moderate to severe plaque psoriasis.Methods:79 patients with moderate and severe plaque psoriasis admitted to Shantou Dermatological and Venereal Disease Prevention and Treatment Hospital from July 2021 to September 2022 were selected as the study objects.Patients were divided into experimental group(n=42)and control group(n=37)by coin toss.The experimental group was treated with ecizumab and the control group was treated with secuchiumab.The treatment results of the two groups were compared and analyzed.Results:There were no significant differences in psoriasis lesion area and severity index(PASI)scores between 2 groups before treatment and 4,8 and 12 weeks after treatment(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The treatment satisfaction rate of experimental group was 95.24%,higher than that of control group 94.29%,but there was no statistical significance between groups(P>0.05).Conclusion:Both ecizumab and secuchiumab have good efficacy and safety in the treatment of moderate and severe plaque psoriasis.